Search Result

Results for "

stable metabolite

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Drug Metabolite (4) Endogenous Metabolite (7) ADC Payload (1) Bradykinin Receptor (1) Calcineurin (1) Cytochrome P450 (1) Drug Isomer (1) Drug-Linker Conjugates for ADC (2) Environmental Pollutants (1) Histamine Receptor (1) HMG-CoA Reductase (HMGCR) (1) Isotope-Labeled Compounds (3) Microtubule/Tubulin (1) PPAR (1) Prostaglandin Receptor (3) Ras (1) Reference Standards (1) Thyroid Hormone Receptor (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (5) Endocrinology (3) Infection (2) Inflammation/Immunology (3) Metabolic Disease (8) Neurological Disease (1)

By Targets:

Drug Metabolite (4)

Endogenous Metabolite (7)

ADC Payload (1)

Bradykinin Receptor (1)

Calcineurin (1)

Cytochrome P450 (1)

Drug Isomer (1)

Drug-Linker Conjugates for ADC (2)

Environmental Pollutants (1)

Histamine Receptor (1)

HMG-CoA Reductase (HMGCR) (1)

Isotope-Labeled Compounds (3)

Microtubule/Tubulin (1)

PPAR (1)

Prostaglandin Receptor (3)

Ras (1)

Reference Standards (1)

Thyroid Hormone Receptor (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (5)

Endocrinology (3)

Infection (2)

Inflammation/Immunology (3)

Metabolic Disease (8)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Drug Metabolite Endogenous Metabolite

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-124489

2-Hydroxyestradiol 2 Publications Verification	Endogenous Metabolite	Metabolic Disease
2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity .

HY-139909A

CL2E-SN38 TFA 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .

HY-131146

AMOZ 1 Publications Verification 3-Amino-5-morpholinomethyl-2-oxazolidone	Drug Metabolite	Infection
AMOZ is a carcinogenic metabolite of Furaltadone (HY-B1148A), which forms stable tissue residues by covalently binding to proteins as a hapten. AMOZ can be coupled with carrier proteins (such as BSA/OVA) to induce immune response and is released after acid hydrolysis. AMOZ residues can be detected by competitive ELISA method, and the detection limit in the monoclonal antibody 2E5.1 test is as low as 0.16 μg/kg (shrimp sample). AMOZ can be used as a typical marker to monitor drug residues in animal-derived foods in the field of food safety[1][2].

HY-111271

L 888607 1 Publications Verification	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
L 888607 is a potent, selective, stable and orally active CRTH2 agonist. L 888607 has high affinity for the human CRTH2 receptor with a K_i value of 4 nM. L 888607 can be used for the research of several physiological events and metabolite .

HY-P1488

Bradykinin (1-5)	Drug Metabolite	Cardiovascular Disease
Bradykinin (1-5) is a major stable metabolite of Bradykinin (HY-P0206), formed by the proteolytic action of angiotensin-converting enzyme (ACE) . Bradykinin (1-5) inhibits α- and γ-thrombin-induced platelet aggregation .

HY-135700

Mevalonolactone	Calcineurin Ras HMG-CoA Reductase (HMGCR)	Metabolic Disease Inflammation/Immunology
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the GGPPS promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-120980

Thromboxane B1 TXB1	Endogenous Metabolite	Cardiovascular Disease
Thromboxane B1 (TXB1) is a stable, inactive endogenous metabolite of Thromboxane A1 (TXA1) .

HY-P1469

Bradykinin (1-6)	Bradykinin Receptor	Cardiovascular Disease Endocrinology
Bradykinin (1-6) is an amino-truncated Bradykinin peptide. Bradykinin (1-6) is a stable metabolite of Bradykinin, cleaved by carboxypeptidase Y (CPY).

HY-130082

DM4-SMe	ADC Payload Microtubule/Tubulin	Cancer
DM4-SMe is a metabolite of antibody-maytansin conjugates (AMCs) and a tubulin inhibitor, and also a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM4-SMe inhibits KB cells with an IC₅₀ of 0.026 nM. DM4-SMe is a highly toxic metabolite that can be oxidized and detoxified by human liver microsomes .

HY-34439

2,5-Dimethylpyrazine NSC 49139	Environmental Pollutants Endogenous Metabolite	Metabolic Disease
2,5-Dimethylpyrazine (NSC 49139) is an endogenous metabolite. 2,5-Dimethylpyrazine in produced in food systems of two whey protein hydrolysates, obtained using either trypsin or proteinase from Aspergillus melleus. 2,5-Dimethylpyrazine can be qualitatively monitored using a stable isotope dilution assay. 2,5-Dimethylpyrazine can also be generated via microbial mechanisms using Bacillus subtilis. 2,5-Dimethylpyrazine can be oxidized to form 5-methylpyrazine-2-carboxylic acid, which is the intermediate in the synthesis of antilipoltic agent. 2,5-Dimethylpyrazine is a volatile compound that can give a roasted peanut flavor .

HY-W060470

1-Methyl-4-imidazoleacetic acid hydrochloride	Histamine Receptor	Neurological Disease
1-Methyl-4-imidazoleacetic acid hydrochloride is a stable metabolite of Histamine (HY-B1204) that is produced by the oxidation of the primary metabolite, N-methylhistamine .

HY-139114

20-Carboxyarachidonic acid	PPAR	Metabolic Disease
20-Carboxyarachidonic acid, a relatively stable metabolite of 20-HETE, is an endogenous dual activator of PPARalpha and PPARgamma .

HY-139909

CL2E-SN38	Drug-Linker Conjugates for ADC	Cancer
CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .

HY-165587

BM-573	Prostaglandin Receptor	Cardiovascular Disease
BM-573 is an orally active dual thromboxane A₂ (TXA₂) modulator with an IC₅₀ of 1.3 nM. BM-573 possesses both thromboxane synthase (TxAS) inhibition and thromboxane receptor (TP) antagonistic effects. BM-573 can completely inhibit platelet aggregation induced by Arachidonic acid (HY-109590) or U-46619 (TXA₂ analogues). BM-573 completely blocks the generation of TXB₂ (the stable metabolite of TXA₂) in human platelets and does not inhibit cyclooxygenase (COX-1/COX-2), thus avoiding interference with other prostaglandin synthesis. BM-573 has an inhibitory effect on U-46619-induced contractions in rat gastric fundus smooth muscle (ED₅₀ = 4.2 μM), but has no effect on contractions caused by PGE₂, PGF₂α, or PGI₂. BM-573 can be used in the study of atherosclerosis, myocardial infarction, pulmonary hypertension and shock .

HY-132569S

8-Hydroxy warfarin-d5	Isotope-Labeled Compounds Drug Metabolite	Others
8-Hydroxy warfarin-d₅ can be used as an internal standard for the quantification of Warfarin and its known metabolites .

HY-117178

TA 0910 acid-type	Thyroid Hormone Receptor	Metabolic Disease
TA 0910 acid-type is a metabolite of TA 0910. TA-0910 is a metabolically stable analogue of thyrotropin releasing hormone (TRH) .

HY-124489S1

2-Hydroxyestradiol-d5	Isotope-Labeled Compounds Endogenous Metabolite	Infection
2-Hydroxyestradiol-d₅ is the deuterium labeled 2-Hydroxyestradiol. 2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity[ .

HY-124489S

2-Hydroxyestradiol-13C6	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
2-Hydroxyestradiol- ¹³C₆ is the ¹³C-labeled 2-Hydroxyestradiol. 2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity .

HY-124489R

2-Hydroxyestradiol (Standard)	Endogenous Metabolite Reference Standards	Metabolic Disease
2-Hydroxyestradiol (Standard) is the analytical standard of 2-Hydroxyestradiol. This product is intended for research and analytical applications. 2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity .

HY-111271B

(R)-L 888607	Prostaglandin Receptor Drug Isomer	Inflammation/Immunology Endocrinology
(R)-L 888607 is the isomer of L 888607 (HY-111271), and can be used as an experimental control. L 888607 is a potent, selective, stable and orally active CRTH2 agonist. L 888607 has high affinity for the human CRTH2 receptor with a K_i value of 4 nM. L 888607 can be used for the research of several physiological events and metabolite .

HY-157925

Bicyclo-PGE1 Bicyclo Prostaglandin E1	Endogenous Metabolite	Others
Bicyclo-PGE1 (Bicyclo Prostaglandin E1) is a stable, base-catalyzed transformation product of the PGE1 metabolite 13,14-dihydro-15-keto PGE1. Bicyclo-PGE1 can be used to estimate the biosynthesis and metabolism of PGE1 in vivo .

HY-179011

CYP3A4-IN-6	Cytochrome P450	Metabolic Disease
CYP3A4-IN-6 (Compound 8a) is a CYP3A4 inhibitor with tissue-selective metabolism. CYP3A4-IN-6 remains stable in the intestinal S9 component but is rapidly metabolized in the liver S9 component, forming a less active metabolite. CYP3A4-IN-6 can be used for intestinal selectivity studies .

HY-P1488A

Bradykinin (1-5) TFA	Drug Metabolite	Cardiovascular Disease
Bradykinin (1-5) (TFA) is a major stable metabolite of Bradykinin (HY-P0206), formed by the proteolytic action of angiotensin-converting enzyme (ACE). Bradykinin (1-5) (TFA) inhibits α- and γ-thrombin-induced platelet aggregation .

Cat. No.	Product Name	Target	Research Area